QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=91D5D4FEC13826811B5F5E1FD1844E50;jsessionid=B9609C0409D604A30702F0E3A3B632C8;jsessionid=CF29DFA4E6E6DF158DF1D00C44C17097;jsessionid=453EEEA855107530A237551FB964447F;jsessionid=E849E1EE440A476F8D89DD6A229D06D4;jsessionid=F9112019BEF1D98203A7866F622D92CC;jsessionid=DC9575FF3C79FCDB776FDDB40101B7D3 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=91D5D4FEC13826811B5F5E1FD1844E50;jsessionid=B9609C0409D604A30702F0E3A3B632C8;jsessionid=CF29DFA4E6E6DF158DF1D00C44C17097;jsessionid=453EEEA855107530A237551FB964447F;jsessionid=E849E1EE440A476F8D89DD6A229D06D4;jsessionid=F9112019BEF1D98203A7866F622D92CC;jsessionid=DC9575FF3C79FCDB776FDDB40101B7D3